Development of an HPLC-UV Method for Quantification of Stattic

Author(s): Soheil Sedaghat, Ommoleila Molavi, Akram Faridi, Ali Shayanfar*, Mohammad Reza Rashidi.

Journal Name: Current Pharmaceutical Analysis

Volume 15 , Issue 6 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Signal transducer and activator of transcription 3 (STAT3), an oncogenic protein found constitutively active in many types of human malignancies, is considered to be a promising target for cancer therapy.

Objective: In this study for the first time, a simple and accurate method has been developed for the determination of a STAT3 dimerization inhibitor called stattic in aqueous and plasma samples.

Methods: A reverse-phase high-performance liquid chromatography (RP-HPLC) composed of C18 column as stationary phase, and the mixture of acetonitrile (60%) and water (40%) as mobile phase with a UV detection at 215 nm were applied for quantification of stattic. The developed method was validated by Food and Drug Administration (FDA) guideline.

Results: The method provided a linear range between 1-40 and 2.5-40 µg mL-1 for aqueous and plasma samples, respectively, with a correlation coefficient of 0.999. The accuracy (as recovery) of the developed method was found to be between 95-105% for aqueous medium and 85-115% for plasma samples. The precision (as relative standard deviation) for aqueous and plasma samples was less than 6% and 15%, respectively. The sensitivity of the developed method based on FDA guideline was 1 µg mL-1 for aqueous and 2.5 µg mL-1 for plasma samples.

Conclusion: These results show that the established method is a fast and accurate quantification for stattic in aqueous and plasma samples.

Keywords: Analysis method, cancer, HPLC-UV, plasma, stattic, validation.

[1]
Yu, H.; Jove, R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105.
[2]
Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 2008, 18(2), 254-267.
[3]
Furtek, S.L.; Backos, D.S.; Matheson, C.J.; Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol., 2016, 11(2), 308-318.
[4]
Wang, X.; Crowe, P.J.; Goldstein, D.; Yang, J-L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol., 2012, 41(4), 1181-1191.
[5]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10(Supplement. 1), S1409-S1421.
[6]
Kraskouskaya, D.; Duodu, E.; Arpin, C.C.; Gunning, P.T. Progress towards the development of SH2 domain inhibitors. Chem. Soc. Rev., 2013, 42(8), 3337-3370.
[7]
Schust, J.; Sperl, B.; Hollis, A.; Mayer, T.U.; Berg, T. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 2006, 13(11), 1235-1242.
[8]
Mohammadian, J.; Molavi, O.; Pirouzpanah, M.B.; Rahimi, A.A.R.; Samadi, N. Stattic enhances the anti-proliferative effect of docetaxel via the Bax/Bcl-2/cyclin B axis in human cancer cells. Process Biochem., 2018, 69, 188-196.
[9]
Leidgens, V.; Proske, J.; Rauer, L.; Moeckel, S.; Renner, K.; Bogdahn, U.; Riemenschneider, M.J.; Proescholdt, M.; Vollmann-Zwerenz, A.; Hau, P.; Seliger, C. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. Oncotarget, 2017, 8(5), 8250-8263.
[10]
Önal, C.; Sagirli, O. Determination of gemifloxacin in human serum by online heart-cutting liquid chromatography: Application to pharmacokinetic study. Curr. Pharm. Anal., 2017, 13(2), 131-137.
[11]
Reddy, P.S.; Jagarlapudi, V.S.K.; Sekharan, C.B. Determination of edoxaban in bulk and in tablet dosage form by stability indicating high-performance liquid chromatography. Pharm. Sci., 2016, 22(1), 35-41.
[12]
Bansal, S.; DeStefano, A. Key elements of bioanalytical method validation for small molecules. AAPS J., 2007, 9(1), E109-E114.
[13]
Ozkan, S.A. Analytical method validation: The importance for pharmaceutical analysis. Pharm. Sci., 2018, 24(1), 1-2.
[14]
Swartz, M.E.; Krull, I.S. Handbook of Analytical Validation; CRC Press: Fl, 2012.
[15]
Džodić, P.; Živanović, L.; Protić, A.; Ivanović, I.; Veličković-radovanović, R.; Spasić, M.; Lukić, S.; Živanović, S. Development and validation of a solid phase extraction-HPLC method for the determination of carbamazepine and its metabolites, carbamazepine epoxide and carbamazepine trans-diol, in plasma. J. Serb. Chem. Soc., 2012, 77(10), 1423-1436.
[16]
Mowafy, H.A.; Alanazi, F.K.; El Maghraby, G.M. Development and validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma. Saudi Pharm. J., 2012, 20(1), 29-34.
[17]
Booth, B.; Arnold, M.E.; DeSilva, B.; Amaravadi, L.; Dudal, S.; Fluhler, E.; Gorovits, B.; Haidar, S.H.; Kadavil, J.; Lowes, S.; Nicholson, R.; Rock, M.; Skelly, M.; Stevenson, L.; Subramaniam, S.; Weiner, R.; Woolf, E. Workshop report: Crystal city V-quantitative bioanalytical method validation and implementation: The 2013 Revised FDA Guidance. AAPS J., 2015, 17(2), 277-288.
[18]
Ershadi, S.; Shayanfar, A. Are LOD and LOQ reliable parameters for sensitivity evaluation of spectroscopic methods? J. AOAC Int., 2018.
[http://dx.doi.org/10.5740/jaoacint.5717-0363]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 6
Year: 2019
Page: [568 - 573]
Pages: 6
DOI: 10.2174/1573412914666180523092957
Price: $58

Article Metrics

PDF: 48
HTML: 4
EPUB: 1
PRC: 1